Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History
Capital Group Private Client Services, Inc.
- $9.94 Billion
- Q3 2024
A detailed history of Capital Group Private Client Services, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 182,899 shares of BGNE stock, worth $35.5 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
182,899
Previous 192,840
5.16%
Holding current value
$35.5 Million
Previous $27.5 Million
49.25%
% of portfolio
0.41%
Previous 0.29%
Shares
13 transactions
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.05 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.25 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.01 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$966 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$720 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...